U.S. questions whether AstraZeneca used old data in trial

U.S. questions whether AstraZeneca used old data in trial

Results from a U.S. trial of AstraZeneca’s COVID-19 vaccine may have included outdated information, which could mean the firm gave an incomplete picture of efficacy data, U.S. federal health officials said early Tuesday.

A spokesman for the drugmaker said Tuesday that the firm was investigating.

AstraZeneca reported Monday that its COVID-19 vaccine offered strong protection to adults of all ages in an expected U.S. study. The finding could help rebuild public confidence in the drug worldwide and bring it closer to approval in the United States.

In the 30,000-person trial, the vaccine was 79% effective in preventing symptomatic cases of COVID-19, including among older adults. There were no serious cases or hospitalizations among vaccinated volunteers, compared with five cases in participants who received placebos. The figure is small, but is consistent with findings in Britain and other countries that the vaccine protects against the worst effects of the disease.

AstraZeneca also said independent safety monitors had not identified serious side effects, and in particular had not identified an increased risk of blood clots like those identified in Europe, which led many countries to briefly suspend vaccinations last week.

But just hours after those encouraging data were released, the U.S. National Institute of Allergy and Infectious Diseases issued an unusual statement.

In its statement, the agency said the Data and Safety Monitoring Board (DSMB) expressed concern that AstraZeneca may have included outdated information from that trial, which could have provided an incomplete picture of the effectiveness data.

We urge the company to work with the DSMB to review the effectiveness data and ensure that the most accurate and up-to-date effectiveness data are published as soon as possible, the text said.

The company expects to file an application with the U.S. Food and Drug Administration (FDA) in the coming weeks, and the government’s outside advisors will have a public discussion of the evidence before the agency makes a decision.

Licensure and recommendations for use of the vaccine in the United States will be up to the FDA and the Centers for Disease Control after a thorough review of the data by independent advisory committees.

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!